Randomized Phase II Study of PET Response–Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial

Karyn A. Goodman, Fang‐Shu Ou, Nathan C. Hall, +15

Journal of Clinical Oncology

BRAF–MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas

Priscilla K. Brastianos, Erin Twohy, Susan Geyer, +25

New England Journal of Medicine

Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic <i>NF2</i> Mutations

Priscilla K. Brastianos, Erin Twohy, Elizabeth R. Gerstner, +42

Journal of Clinical Oncology

Stereotactic Radiosurgery With or Without Whole-Brain Radiation Therapy for Limited Brain Metastases: A Secondary Analysis of the North Central Cancer Treatment Group N0574 (Alliance) Randomized Controlled Trial

Thomas M. Churilla, Karla V. Ballman, Paul D. Brown, +18

International Journal of Radiation Oncology*Biology*Physics

Adaptive RadiotherapyNeuro-oncologyLimited Brain MetastasesRadiation TherapyMedicine +7

BACCI: A phase II randomized, double-blind, multicenter, placebo-controlled study of capecitabine (C) bevacizumab (B) plus atezolizumab (A) or placebo (P) in refractory metastatic colorectal cancer (mCRC): An ACCRU network study

Niharika B. Mettu, Erin Twohy, Fang‐Shu Ou, +16

Annals of Oncology

A phase 1 and randomized, placebo‐controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872

Evanthia Galanis, S. Keith Anderson, Erin Twohy, +11

Cancer

Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572

David Schiff, Kurt A. Jaeckle, S. Keith Anderson, +11

Cancer

CALGB (Alliance) 40603: Long-term outcomes (LTOs) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) and bevacizumab (Bev) in triple-negative breast cancer (TNBC).

William M. Sikov, Mei‐Yin C. Polley, Erin Twohy, +17

Journal of Clinical Oncology

Surgical OncologyBreast OncologyCancer ManagementPathologyResidual Cancer Burden +16

Survival outcomes from CALGB 80803 (Alliance): A randomized phase II trial of PET scan-directed combined modality therapy for esophageal cancer.

Karyn A. Goodman, Nathan C. Hall, Tanios Bekaii‐Saab, +10

Journal of Clinical Oncology

Surgical OncologyCalgb 80803Esophageal CancerMultimodalitySurgery +15

Alliance A071401: Phase II trial of FAK inhibition in meningiomas with somatic NF2 mutations.

Priscilla K. Brastianos, Erin Twohy, Elizabeth R. Gerstner, +17

Journal of Clinical Oncology

Neuro-oncologyRecurrent MeningiomasSystems BiologySomatic VariantAlliance A071401 +12